STEPHANIE COX: Open Payments
NPI 1508510553 · WILLIAMSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,632 in 83 payments from 23 companies in 2025. Trend: 2023 $554 · 2024 $2,040 · 2025 $1,632
Food & beverage: $1,632
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $247 |
| Lilly USA, LLC | 7 | $242 |
| GlaxoSmithKline, LLC. | 9 | $177 |
| AstraZeneca Pharmaceuticals LP | 7 | $152 |
| PFIZER INC. | 9 | $141 |
| Novo Nordisk Inc | 6 | $129 |
| Lundbeck LLC | 4 | $74 |
| Amgen Inc. | 3 | $52 |
| Abbott Laboratories | 2 | $47 |
| Endo USA, Inc. | 2 | $46 |
Products named: MOUNJARO, QULIPTA, FARXIGA, VRAYLAR, TRELEGY ELLIPTA, REXULTI, PAXLOVID, SHINGRIX.
Industry payments across VA — which companies pay providers there.
